1

Richard CarterHead of Industry Sponsorship

Department of HealthLondon

2

Presentation

Co-operation of public authorities and industry: why is it necessary to work together?

The UK experience

3

Outline of the presentation

The DH role in co-ordinating policy Our aim and why we do this How we go about it

- Pharmaceuticals

- Medical technology Characteristics of the relationship

5

Our aim:

The Government's strategy is to build on the UK’s reputation as being a leader in life sciences, and to work

with both industries to improve the environment for them to continue to innovate.

6

Importance of these industries to the economy of the UK

Vital role of each sector in supporting Government’s health goals and policies

Importance of innovation to health care reform

Why do we do this?

7

Pharmaceutical & Medical Technology sectors in the UK

Pharmaceutical Industry Invests over £3bn annually in

R&D in the UK £12bn of medicines exported

from the UK annually 68,000 directly employed by

the pharmaceutical industry 16 of the worlds top-selling 75

medicines discovered in the UK

Medical technology Annual output is in the region

of £4bn including £2.2bn to the NHS

Exports are about £2bn 55,000 directly employed by

the medical technology industry

8

How do we go about it? – Pharmaceuticals

History of the relationship is long Since 1999 more systematic architecture of engagement 1999-2001 PICTF 2001-present MISG MISG - industry side membership global, government

side ministers and top officials Meets twice a year Joint consideration of strategic issues of common

interest, e.g. science education

9

Close Dialogue & Partnership with Industry-MISG & Long Term Leadership Strategy

Ministerial Industry Strategy Group (MISG)

MISG has overseen the development of the Long Term Leadership Strategy for Medicines (LTLS) which is designed to:

secure the provision of safe and effective medicines for patients;

maintain and strengthen the UK pharmaceutical industry within Europe;

and to advance healthcare innovation in the UK.

10

Close Dialogue & Partnership with Industry- MISG - Long Term Leadership Strategy

Three workstreams have reported on their conclusions:

Partnership Working Group: Dealing with the industry’s relationships with the NHS in England and with uptake of cost effective medicines

European Working Group: Improving the business and technology environment for the pharmaceutical industry in Europe

Regulatory Working Group: Developing the regulatory environment in the UK and Europe so as better to serve needs of all stakeholders

11

Pharmaceuticals - LTLS Report February 2007

12

How do we go about it – Medical Technology

Shorter history of joint engagement Healthcare Industries Task Force (HITF) a year long joint Initiative was set up in 2003 Beginning of an important dialogue between Government and the sector Implementation of its key outputs from 2004 New strategic group – Ministerial Medical Technology Strategy Group – set up to take forward recommendations Will meet twice a year Will consider strategic issues of common interest, e.g. small business support in this sector, innovation

13

Key outputs of HITF

Integration of technology evaluation into procurement - Centre for Evidence-based Purchasing (CEP) Establishment of a National Innovation Centre (NIC) Strengthened R&D environment for medical technologies Streamlined procurement process Continuing shared strategic agenda and architecture within

which to pursue it

14

Medical Technology - Published Reports 2004 and 2007

Further details are available on: www.advisorybodies.doh.gov.uk/hitf

15

Characteristics of the relationships

Well established long term engagement Very senior representation from both sides on the two

joint government/industry groups Genuine interest on both sides in holding constructive

dialogue at strategic level Openness and transparency Ability to disagree without rupturing the connection Strong horizontal working across relevant government

departments

16

The UK Government pharmaceuticalpharmaceutical & medical technologymedical technology Industry linkages: a schematic overview

DHCo-ordination

& policy/ Purchaser/NHS

MHRAEU medicines/device

legislationNICE

Appraisals ofNew technologies

HOAnimal rights

legislation

HMTTax incentives/Science strategy

DBERRScience base

FCO/UKTIInward investment

DFIDAccess to medicines

UKCRCTranslational

Clinical research

OSCHRHealth research

NHS PASAProcurement,

device evaluation

PharmaceuticalsMedical Technology

NHSIII/NIC

DIUSSkills

17

Key Messages

Government committed to a strong relationship with industry

Both parties to the relationship benefit

Working in partnership wherever possible has enabled us to achieve many shared goals